HRP20110732T1 - Antivirusni spojevi - Google Patents
Antivirusni spojevi Download PDFInfo
- Publication number
- HRP20110732T1 HRP20110732T1 HR20110732T HRP20110732T HRP20110732T1 HR P20110732 T1 HRP20110732 T1 HR P20110732T1 HR 20110732 T HR20110732 T HR 20110732T HR P20110732 T HRP20110732 T HR P20110732T HR P20110732 T1 HRP20110732 T1 HR P20110732T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- aryl
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005421 aryl sulfonamido group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- -1 imido Chemical group 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj formule I: ili njegova farmaceutski prihvatljiva sol, enantiomer ili solvat, naznačeni time štoR1 je nezavisno izabran iz grupe koju čine H, alkil, alkenil, alkinil, aril, cikloalkil, heterociklus, halogen, haloalkil, alkilsulfonamido, arilsulfonamido, -C(O)NHS(O)2- ili -S(O)2-, izborno supstituiran sa jednim ili više A3;R2 je -C(Y1)(A3),R3 je H ili (C1-6)alkil; Y1 je nezavisno O, S, N(A3);Z je O; Z1 je -Y1-A3;Z2a je H, (C1-10)alkil, (C2-10)alkenil ili (C2-10)alkinil ili Z2a izborno formira prsten sa Q1;Z2b je H, (C1-6)alkil, (C2-8)alkenil ili (C2-8)alkinil; Q1 je (C1-8)alkil, (C2-8)alkenil ili (C2-8)alkinil; A3 je nezavisno izabran iz grupe koju čine -OH, -C(O)OH, alkil, alkenil, alkinil, amino, amido, imido, imino, halogen, CF3, CH2CF3, cikloalkil, nitro, aril, aralkil, alkoksi, ariloksi, heterociklus, heteroaril, -C(A2)3, - C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -(CH2)m-heterociklus,- (CH2)mC(O)Oalkil, -O-(CH2)m-O-C(O)-Oalkil, -O-(CH2)m-O-C(O)-(CH2)m-alkil, -(CH2)mO-C(O)-O-alkil, -(CH2)mO-C(O)-O-cikloalkil,
Claims (11)
1. Spoj formule I:
[image]
ili njegova farmaceutski prihvatljiva sol, enantiomer ili solvat, naznačeni time što
R1 je nezavisno izabran iz grupe koju čine H, alkil, alkenil, alkinil, aril, cikloalkil, heterociklus, halogen, haloalkil, alkilsulfonamido, arilsulfonamido, -C(O)NHS(O)2- ili -S(O)2-, izborno supstituiran sa jednim ili više A3;
R2 je -C(Y1)(A3),
R3 je H ili (C1-6)alkil;
Y1 je nezavisno O, S, N(A3);
Z je O;
Z1 je -Y1-A3;
Z2a je H, (C1-10)alkil, (C2-10)alkenil ili (C2-10)alkinil ili Z2a izborno formira prsten sa Q1;
Z2b je H, (C1-6)alkil, (C2-8)alkenil ili (C2-8)alkinil;
Q1 je (C1-8)alkil, (C2-8)alkenil ili (C2-8)alkinil;
A3 je nezavisno izabran iz grupe koju čine -OH, -C(O)OH, alkil, alkenil, alkinil, amino, amido, imido, imino, halogen, CF3, CH2CF3, cikloalkil, nitro, aril, aralkil, alkoksi, ariloksi, heterociklus, heteroaril, -C(A2)3, - C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -(CH2)m-heterociklus,- (CH2)mC(O)Oalkil, -O-(CH2)m-O-C(O)-Oalkil, -O-(CH2)m-O-C(O)-(CH2)m-alkil, -(CH2)mO-C(O)-O-alkil, -(CH2)mO-C(O)-O-cikloalkil, -N(H)C(Me)C(O)O-alkil ili alkoksi arilsulfonamid, pri čemu svako A3 može biti izborno supstituiran sa 1 do 4 -R1, halogen, alkil, alkenil, alkinil, aril, carbocycle, heterociklus, aralkil, aril sulfonamid, aril alkilsulfonamid, ariloksi sulfonamid, ariloksi alkilsulfonamid, ariloksi arilsulfonamid, alkil sulfonamid, alkiloksi sulfonamid, alkiloksi alkilsulfonamid, -(CH2)mheterociklus, -(CH2)m-C(O)O-alkil, -O(CH2)mOC(O)Oalkil, -O-(CH2)m-O-C(O)-(CH2)m-alkil, -(CH2)m-O-C(O)-O-alkil, -(CH2)m-O-C(O)-O-cikloalkil, -N(H)C(CH3)C(O)O-alkil ili alkoksi arilsulfonamid grupe, izborno supstituirane sa R1;
A2 je nezavisno izabran iz grupe koju čine H, alkil, alkenil, alkinil, amino, aminokiselina, alkoksi, ariloksi, cijano, haloalkil, cikloalkil, aril, heteroaril, alkilsulfonamid ili arilsulfonamid; i
m je 0 do 6,
pri čemu, ako nije drugačije naznačeno, alkil je (C1-18)alkil; alkenil je (C2-18)alkenil; alkinil je (C2-18)alkinil; cikloalkil je (C3-7)cikloalkil; aril je (C6-20)aril; aralkil je (C6-20)aralkil; alkoksi je (C1-18)alkoksi; karbociklus je zasićeni, nezasićeni ili aromatični (C3-7)monociklus, (C7-12)biciklus ili policiklus sa do 20 atoma ugljika; heterociklus je karbociklus kao što je prethodno definirano, u kojem su 1, 2, 3 ili 4 atoma ugljika zamijenjeni sa O, N ili S.
2. Spoj prema patentnom zahtjevu 1 koji ima formulu XI:
[image]
ili njegova farmaceutski prihvatljiva sol, enantiomer ili solvat,
naznačeni time što:
svako R1, R2, R3, Z, Z1, Z2b, m, A3, i A2 su kao što su definirani u patentnom zahtjevu 1; i
Z2a formira prsten sa Q1.
3. Spoj prema patentnom zahtjevu 2, naznačen time što je Z1 jednako O-A3.
4. Spoj patentnom zahtjevu 2 koji ima formulu XXVI:
[image]
ili njegova farmaceutski prihvatljiva sol, enantiomer ili solvat,
naznačeni time što:
svako R1, R2, R3, Z, Z2a, Z2b, Q1, m, A3, i A2 su kao što su definirani u patentnom zahtjevu 2; i
L je nezavisno izabran iz grupe koju čine C ili N, uz uvjet da nema više od tri uzastopna N, pri čemu je svaki izborno supstituiran sa jednim ili više A3.
5. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time što sadrži i najmanje jedan farmaceutski prihvatljiv nosač.
6. Farmaceutska kompozicija prema patentnom zahtjevu 5, naznačena time što se koristi za primjenu u liječenju poremećaja povezanih sa HCV-om.
7. Farmaceutska kompozicija prema patentnom zahtjevu 5 ili 6, naznačena time što dodatno sadrži nukleozidni analog.
8. Farmaceutska kompozicija prema patentnom zahtjevu 5 ili 6, naznačena time što dodatno sadrži interferon ili pegilirani interferon.
9. Farmaceutska kompozicija prema patentnom zahtjevu 7, naznačena time što je navedeni nukleozidni analog izabran iz grupe koju čine ribavirin, viramidin, levovirin, L-nukleozid i izatoribin i navedeni interferon je α-interferon ili pegilirani interferon.
10. Uporaba spoja prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time što se koristi za pripremu lijeka za liječenje hepatitisa C ili poremećaja povezanog sa hepatitisom C.
11. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time što se koristi za primjenu u postupku za liječenje hepatitisa C ili poremećaja povezanog sa hepatitisom C.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58863304P | 2004-07-16 | 2004-07-16 | |
| US59163504P | 2004-07-27 | 2004-07-27 | |
| PCT/US2005/025503 WO2006020276A2 (en) | 2004-07-16 | 2005-07-18 | Antiviral compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110732T1 true HRP20110732T1 (hr) | 2011-11-30 |
Family
ID=35447172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20070043A HRP20070043A2 (hr) | 2004-07-16 | 2007-02-09 | Antivirusna sredstva |
| HR20110732T HRP20110732T1 (hr) | 2004-07-16 | 2011-10-11 | Antivirusni spojevi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20070043A HRP20070043A2 (hr) | 2004-07-16 | 2007-02-09 | Antivirusna sredstva |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20080311077A1 (hr) |
| EP (2) | EP1778702B1 (hr) |
| JP (2) | JP5676839B2 (hr) |
| KR (1) | KR20070034119A (hr) |
| AP (1) | AP2461A (hr) |
| AR (1) | AR050174A1 (hr) |
| AT (1) | ATE516293T1 (hr) |
| AU (1) | AU2005274700B2 (hr) |
| BR (1) | BRPI0513426A (hr) |
| CA (1) | CA2571984C (hr) |
| CY (1) | CY1112453T1 (hr) |
| DK (1) | DK1778702T3 (hr) |
| EA (1) | EA200700336A1 (hr) |
| ES (1) | ES2468441T3 (hr) |
| HK (1) | HK1103089A1 (hr) |
| HR (2) | HRP20070043A2 (hr) |
| IL (1) | IL180288A0 (hr) |
| MX (1) | MX2007000584A (hr) |
| NO (1) | NO20070866L (hr) |
| NZ (1) | NZ552405A (hr) |
| PL (2) | PL382845A1 (hr) |
| PT (1) | PT1778702E (hr) |
| RS (1) | RS51974B (hr) |
| TW (2) | TW201228665A (hr) |
| WO (1) | WO2006020276A2 (hr) |
Families Citing this family (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| US7273851B2 (en) * | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| CA2615666C (en) * | 2005-07-25 | 2014-08-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| DE602006019323D1 (de) | 2005-10-11 | 2011-02-10 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5473334B2 (ja) | 2005-12-23 | 2014-04-16 | ジーランド ファーマ アクティーゼルスカブ | 修飾リジン模倣化合物 |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| AP2008004721A0 (en) * | 2006-07-07 | 2008-12-31 | Gilead Sciences Inc | Antiviral phosphinate compounds |
| EP2422791B1 (en) * | 2006-07-07 | 2014-12-17 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| AU2013200563C1 (en) * | 2006-07-07 | 2015-05-14 | Gilead Sciences, Inc. | Antiviral phosphinate compounds |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| AU2007294872A1 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Macrocyclic HCV inhibitors and their uses |
| US8377873B2 (en) * | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20080188545A1 (en) | 2006-12-21 | 2008-08-07 | Alimardanov Asaf R | Synthesis of pyrrolidine compounds |
| US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
| WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
| CN101627020B (zh) * | 2007-02-08 | 2015-06-17 | 泰博特克药品有限公司 | 抑制hcv的大环苯基氨基甲酸酯 |
| WO2008134397A1 (en) * | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
| US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
| WO2008141227A1 (en) | 2007-05-10 | 2008-11-20 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
| AU2008271117B2 (en) | 2007-06-29 | 2013-10-24 | Gilead Sciences, Inc. | Antiviral compounds |
| AP2874A (en) * | 2007-06-29 | 2014-03-31 | Gilead Sciences Inc | Antiviral compounds |
| AU2014200403B2 (en) * | 2007-06-29 | 2016-05-19 | Gilead Sciences, Inc. | Antiviral compounds |
| AR067180A1 (es) * | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Compuestos antivirales |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| WO2009064955A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| US8263549B2 (en) * | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| CN104557880A (zh) | 2007-12-21 | 2015-04-29 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| MX2010006736A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| MX2010008523A (es) * | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
| WO2009117594A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
| US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5723783B2 (ja) | 2008-12-10 | 2015-05-27 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製の阻害剤としての新しい４−アミノ−４−オキソブタノイルペプチド |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2417134B1 (en) | 2009-04-08 | 2017-05-17 | Idenix Pharmaceuticals LLC. | Macrocyclic serine protease inhibitors |
| KR20140122705A (ko) | 2009-05-13 | 2014-10-20 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| KR20100127948A (ko) * | 2009-05-27 | 2010-12-07 | 한국전자통신연구원 | Ｓａｒｓ 코로나바이러스의 검출 및 억제용 펩타이드 화합물 및 그의 응용 |
| US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US7924650B2 (en) * | 2009-06-30 | 2011-04-12 | Oracle America, Inc. | Dynamically controlled voltage regulator for a memory |
| AR077712A1 (es) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | Inhibidores de serina proteasa macrociclica |
| US8927484B2 (en) * | 2009-12-03 | 2015-01-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| EP3284741A1 (en) | 2010-11-17 | 2018-02-21 | Gilead Pharmasset LLC | Antiviral compounds |
| US8937041B2 (en) | 2010-12-30 | 2015-01-20 | Abbvie, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| MX2013007698A (es) | 2010-12-30 | 2013-08-15 | Abbvie Inc | Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina. |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| TWI635093B (zh) | 2011-05-19 | 2018-09-11 | 基利科學股份有限公司 | 用於製備抗ｈｉｖ藥劑的方法與中間物 |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101890400B1 (ko) | 2011-11-16 | 2018-08-21 | 길리애드 파마셋 엘엘씨 | 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸 |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| CA2887621A1 (en) | 2012-10-08 | 2014-04-17 | Abbvie Inc. | Compounds useful for making hcv protease inhibitors |
| WO2014062196A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2970335B1 (en) | 2013-03-15 | 2019-05-08 | Gilead Sciences, Inc. | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
| EP2970192A1 (en) | 2013-03-15 | 2016-01-20 | Achillion Pharmaceuticals, Inc. | Sovaprevir polymorphs and methods of manufacture thereof |
| US9962251B2 (en) | 2013-10-17 | 2018-05-08 | Boston Scientific Scimed, Inc. | Devices and methods for delivering implants |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| ES2870106T3 (es) | 2017-05-05 | 2021-10-26 | Zealand Pharma As | Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético |
| PL3661937T3 (pl) | 2017-08-01 | 2021-12-20 | Gilead Sciences, Inc. | Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych |
| AU2018378832B9 (en) | 2017-12-07 | 2021-05-27 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) * | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) * | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| CA2083386C (en) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Phosphorous prodrugs |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| EE04023B1 (et) * | 1996-10-18 | 2003-04-15 | Vertex Pharmaceuticals Incorporated | Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid |
| US6018049A (en) * | 1996-12-26 | 2000-01-25 | Shionogi & Co., Ltd. | Process for the preparation of carbamoylated imidazole derivatives |
| PT1003775E (pt) | 1997-08-11 | 2005-07-29 | Boehringer Ingelheim Ca Ltd | Peptidos inibidores da hepatite c |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP3889708B2 (ja) | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎トリペプチド阻害剤 |
| EP1377568A1 (en) * | 2001-01-31 | 2004-01-07 | Warner-Lambert Company LLC | Method for carbamoylating alcohols |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2361011T3 (es) | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
| ES2350201T3 (es) | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
-
2005
- 2005-07-18 NZ NZ552405A patent/NZ552405A/en not_active IP Right Cessation
- 2005-07-18 RS RS20110436A patent/RS51974B/en unknown
- 2005-07-18 MX MX2007000584A patent/MX2007000584A/es active IP Right Grant
- 2005-07-18 JP JP2007521717A patent/JP5676839B2/ja not_active Expired - Fee Related
- 2005-07-18 PT PT05791144T patent/PT1778702E/pt unknown
- 2005-07-18 EP EP05791144A patent/EP1778702B1/en active Active
- 2005-07-18 BR BRPI0513426-9A patent/BRPI0513426A/pt not_active IP Right Cessation
- 2005-07-18 AT AT05791144T patent/ATE516293T1/de active
- 2005-07-18 AR ARP050102967A patent/AR050174A1/es not_active Application Discontinuation
- 2005-07-18 EP EP10178084.9A patent/EP2316839B1/en active Active
- 2005-07-18 WO PCT/US2005/025503 patent/WO2006020276A2/en active Application Filing
- 2005-07-18 US US11/632,180 patent/US20080311077A1/en not_active Abandoned
- 2005-07-18 PL PL382845A patent/PL382845A1/pl not_active Application Discontinuation
- 2005-07-18 AP AP2007003895A patent/AP2461A/xx active
- 2005-07-18 CA CA2571984A patent/CA2571984C/en not_active Expired - Fee Related
- 2005-07-18 DK DK05791144.8T patent/DK1778702T3/da active
- 2005-07-18 AU AU2005274700A patent/AU2005274700B2/en not_active Ceased
- 2005-07-18 PL PL05791144T patent/PL1778702T3/pl unknown
- 2005-07-18 KR KR1020077003918A patent/KR20070034119A/ko active IP Right Grant
- 2005-07-18 ES ES10178084.9T patent/ES2468441T3/es active Active
- 2005-07-18 EA EA200700336A patent/EA200700336A1/ru unknown
- 2005-07-18 US US11/184,429 patent/US7642339B2/en active Active
- 2005-07-19 TW TW101104372A patent/TW201228665A/zh unknown
- 2005-07-19 TW TW094124376A patent/TW200614996A/zh unknown
-
2006
- 2006-12-25 IL IL180288A patent/IL180288A0/en unknown
-
2007
- 2007-02-09 HR HR20070043A patent/HRP20070043A2/hr not_active Application Discontinuation
- 2007-02-15 NO NO20070866A patent/NO20070866L/no not_active Application Discontinuation
- 2007-10-26 HK HK07111565.5A patent/HK1103089A1/xx unknown
-
2011
- 2011-10-10 CY CY20111100970T patent/CY1112453T1/el unknown
- 2011-10-11 HR HR20110732T patent/HRP20110732T1/hr unknown
-
2012
- 2012-02-06 JP JP2012023052A patent/JP5767984B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110732T1 (hr) | Antivirusni spojevi | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| JP2010532352A5 (hr) | ||
| CA2615921C (en) | Hepatitis c inhibitor peptide analogs with a quinoline or a thienopyridine moiety | |
| JP4398424B2 (ja) | Ｃ型肝炎ウィルスに対する活性を有する大環状ペプチド | |
| RU2428428C2 (ru) | Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| CA2549851C (en) | Macrocyclic peptides active against the hepatitis c virus | |
| HRP20100048T1 (hr) | Inhibitori hcv ns-3 serin proteaze | |
| CA2536182C (en) | Macrocyclic peptides active against the hepatitis c virus | |
| AU2007321182B2 (en) | Macrocyclic inhibitors of hepatitis C virus | |
| HRP20151075T1 (hr) | Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat | |
| HRP20110193T1 (hr) | Inhibitor hcv nukleozida | |
| ME02875B (me) | Inhibitori hcv polimeraze | |
| HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
| JP2010508361A5 (hr) | ||
| ME01231B (me) | Makrociklički inhibitori virusa hepatitisa C | |
| JP2012504632A5 (hr) | ||
| HRP20160083T1 (hr) | Makrocikliäśki inhibitori serinske proteaze virusa hepatitisa c izvedeni iz prolina | |
| RU2427372C2 (ru) | Применение санглиферина для лечения вируса гепатита с | |
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| JP2002522557A5 (hr) | ||
| CA2338946A1 (en) | Hepatitis c inhibitor tri-peptides | |
| IL160769A (en) | Heterocyclic compounds and pharmaceutical compositions containing the same | |
| JP2013514359A5 (hr) | ||
| ME00816B (me) | JEDINJENJA l FARMACEUTSKE KOMPOZICIJE ZA TRETMAN VIRUSNIH INFEKCIJA |